Clinical Trial

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2018-12-24; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2021-06-04
Status change: Not Yet Recruiting → Recruiting 2019-10-31
Trial Details
NCT Number NCT03787680
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Prostate Cancer
Enrollment 49 participants
Start Date 2019-10-31
Primary Completion 2023-01-26 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-23